Kepivance (Swedish Orphan Biovitrum AB (publ))
Welcome to the PulseAid listing for the Kepivance drug offered from Swedish Orphan Biovitrum AB (publ). This Fibroblast Growth Factor 7 [Chemical/Ingredient],Increased Epithelial Proliferation [PE],Mucocutaneous Epithelial Cell Growth Factor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Swedish Orphan Biovitrum AB (publ) |
NON-PROPRIETARY NAME: | palifermin |
SUBSTANCE NAME: | PALIFERMIN |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Fibroblast Growth Factor 7 [Chemical/Ingredient],Increased Epithelial Proliferation [PE],Mucocutaneous Epithelial Cell Growth Factor [EPC] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2009-12-15 |
END MARKETING DATE: | 0000-00-00 |
Kepivance HUMAN PRESCRIPTION DRUG Details:
Item Description | Kepivance from Swedish Orphan Biovitrum AB (publ) |
LABELER NAME: | Swedish Orphan Biovitrum AB (publ) |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 6.25(mg/1.2mL) |
START MARKETING DATE: | 2009-12-15 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 66658-112_f5a852da-1b94-4f48-a4c9-7737dc814d03 |
PRODUCT NDC: | 66658-112 |
APPLICATION NUMBER: | BLA125103 |
Other PALIFERMIN Pharmaceutical Manufacturers / Labelers: